Helmy Eltoukhy Ph.D.
Net Worth
Last updated:
What is Helmy Eltoukhy Ph.D. net worth?
The estimated net worth of Dr. Helmy Eltoukhy Ph.D. is at least $706,179,804 as of 30 Sep 2024. He owns shares worth $119,941,900 as insider, has earned $584,583,944 from insider trading and has received compensation worth at least $1,653,960 in Guardant Health, Inc..
What is the salary of Helmy Eltoukhy Ph.D.?
Dr. Helmy Eltoukhy Ph.D. salary is $275,660 per year as Co-Founder, Co-Chief Executive Officer & Chairman in Guardant Health, Inc..
How old is Helmy Eltoukhy Ph.D.?
Dr. Helmy Eltoukhy Ph.D. is 46 years old, born in 1979.
What stocks does Helmy Eltoukhy Ph.D. currently own?
As insider, Dr. Helmy Eltoukhy Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Guardant Health, Inc. (GH) | Co-Founder, Co-Chief Executive Officer & Chairman | 2,049,238 | $58.53 | $119,941,900 |
What does Guardant Health, Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Helmy Eltoukhy Ph.D. insider trading
Guardant Health, Inc.
Dr. Helmy Eltoukhy Ph.D. has made 56 insider trades between 2019-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 565,192 units of GH stock on 1 Jan 2021. As of 30 Sep 2024 he still owns at least 2,049,238 units of GH stock.
Guardant Health key executives
Guardant Health, Inc. executives and other stock owners filed with the SEC:
- Dr. AmirAli Talasaz Ph.D. (46) Co-Chief Executive Officer & Director
- Dr. Helmy Eltoukhy Ph.D. (46) Co-Founder, Co-Chief Executive Officer & Chairman
- Mr. John G. Saia (52) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Michael J. Wiley (49) Head of Corporation Affairs